(Q46605974)

English

Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study).

scientific article published on 2 August 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23912798

Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). (English)

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23912798

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

Philip G Conaghan

4

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23912798

16

object named as

P Emery

0 references

Elizabeth M A Hensor

3

object named as

E M A Hensor

0 references

Richard J. Wakefield

15

object named as

R J Wakefield

0 references

6

object named as

M H Buch

1 reference

Europe PubMed Central

23 December 2017

author name string

J L Nam

1

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23912798

E Villeneuve

2

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23912798

H I Keen

5

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23912798

A K Gough

7

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23912798

M J Green

8

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23912798

P S Helliwell

9

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23912798

A M Keenan

10

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23912798

A W Morgan

11

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23912798

M Quinn

12

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23912798

R Reece

13

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23912798

D M van der Heijde

14

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23912798

language of work or name

0 references

publication date

2 August 2013

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23912798

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23912798

73

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23912798

1

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23912798

75-85

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23912798

Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

Treating rheumatoid arthritis to target: recommendations of an international task force

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolon

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA s

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203440

21 January 2018

Identifiers

10.1136/ANNRHEUMDIS-2013-203440

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23912798

10.1136/ANNRHEUMDIS-2013-203440

0 references

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23912798

ResearchGate publication ID

0 references

2-s2.0-84889677643

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46605974&oldid=1547652860"